BPD
MCID: BRN056
MIFTS: 48

Bronchopulmonary Dysplasia (BPD) malady

Categories: Rare diseases, Respiratory diseases, Fetal diseases

Aliases & Classifications for Bronchopulmonary Dysplasia

Aliases & Descriptions for Bronchopulmonary Dysplasia:

Name: Bronchopulmonary Dysplasia 38 50 56 52 69
Bpd 50 56

Characteristics:

Orphanet epidemiological data:

56
bronchopulmonary dysplasia
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Infancy,Neonatal; Age of death: normal life expectancy;

Classifications:



External Ids:

Orphanet 56 ORPHA70589
MESH via Orphanet 43 D001997
UMLS via Orphanet 70 C0006287
ICD10 via Orphanet 34 P27.1

Summaries for Bronchopulmonary Dysplasia

MalaCards based summary : Bronchopulmonary Dysplasia, also known as bpd, is related to borderline personality disorder and pulmonary hypertension, neonatal. An important gene associated with Bronchopulmonary Dysplasia is SCGB1A1 (Secretoglobin Family 1A Member 1), and among its related pathways/superpathways are Interleukin-4 and 13 signaling and Transcriptional misregulation in cancer. The drugs RespiGam and Procaterol have been mentioned in the context of this disorder. Affiliated tissues include Lung and Lung, and related phenotypes are homeostasis/metabolism and cardiovascular system

Wikipedia : 71 Bronchopulmonary dysplasia (BPD; formerly chronic lung disease of infancy) is a chronic lung disorder of... more...

Related Diseases for Bronchopulmonary Dysplasia

Diseases related to Bronchopulmonary Dysplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 87)
id Related Disease Score Top Affiliating Genes
1 borderline personality disorder 11.4
2 pulmonary hypertension, neonatal 10.9
3 bronchial disease 10.9
4 pulmonary hypertension 10.4
5 chromophobe adenoma 10.3 CXCL8 SELL
6 partial atrioventricular canal 10.2 SCGB1A1 SFTPB
7 chorioamnionitis 10.2
8 endotheliitis 10.2
9 penis squamous cell carcinoma 10.2 SCGB1A1 SFTPB
10 coronary arterial fistulas 10.2 CXCL8 IL1RN
11 scleroderma, familial progressive 10.2 CXCL8 ELANE
12 adnp syndrome 10.2 CXCL8 ELANE SFTPB
13 cardiomyopathy diabetes deafness 10.2 CXCL8 ELANE
14 esophagus lymphoma 10.2 CXCL8 SCGB1A1 SFTPB
15 benign focal seizures of adolescence 10.1 ELANE TIMP1
16 baritosis 10.1 CXCL8 SCGB1A1 SOD1
17 lung disease 10.1
18 autoimmune polyendocrine syndrome type 1 10.1 CXCL8 TIMP1
19 personality disorder 10.1
20 skin conditions 10.1 CXCL8 IL1RN SCGB1A1
21 mitochondrial dna depletion syndrome 4b 10.1 FGF10 RBP4
22 nervous system cancer 10.1 CXCL8 SFTPB TIMP1
23 nablus mask-like facial syndrome 10.1 ITGAM SELL
24 anogenital venereal wart 10.1 ELANE SCGB1A1 SFTPB
25 bone angioendothelial sarcoma 10.1 CXCL8 IL1RN TIMP1
26 burns 10.1 CXCL8 SCGB1A1 TIMP1
27 infancy electroclinical syndrome 10.1 CXCL8 ELANE FLT1
28 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis 10.1 ELANE SELL TIMP1
29 pleural tuberculosis 10.0 FLT1 SOD1
30 patent ductus arteriosus 10.0
31 major depressive disorder and accelerated response to antidepressant drug treatment 10.0 CXCL8 ELANE ITGAM
32 subcorneal pustular dermatosis 10.0 CXCL8 ELANE SFTPB
33 rectum squamous cell carcinoma 10.0 CXCL8 ELANE SCGB1A1 SFTPB
34 eating disorder 10.0 ELANE ITGAM SELL
35 perrault syndrome 10.0 ITGAM SELL TIMP1
36 xerophthalmia 10.0 ITGAM SELL TIMP1
37 optic nerve glioma 10.0 ELANE RNASE3
38 histiocytosis 10.0 CXCL8 ELANE IL1RN TIMP1
39 infectious anterior uveitis 10.0 CXCL8 ELANE RNASE3
40 intratubular embryonal carcinoma 10.0 CXCL8 ELANE IL1RN TIMP1
41 omsk hemorrhagic fever 10.0 CXCL8 ELANE ITGAM SELL
42 retinitis pigmentosa 51 10.0 CXCL8 ELANE RNASE3
43 familial renal papillary carcinoma 9.9 CXCL8 ELANE RNASE3
44 spontaneous ocular nystagmus 9.9 CXCL8 ELANE RNASE3
45 respiratory failure 9.9
46 acute chest syndrome 9.9 CXCL8 ELANE RNASE3
47 cycloplegia 9.9 ELANE FLT1
48 malignant peritoneal solitary fibrous tumor 9.9 CXCL8 RNASE3 SCGB1A1
49 wilson-mikity syndrome 9.9
50 bare lymphocyte syndrome, type i 9.8 CXCL8 ELANE IL1RN RNASE3

Graphical network of the top 20 diseases related to Bronchopulmonary Dysplasia:



Diseases related to Bronchopulmonary Dysplasia

Symptoms & Phenotypes for Bronchopulmonary Dysplasia

MGI Mouse Phenotypes related to Bronchopulmonary Dysplasia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.9 SOD1 TIMP1 ELANE FGF10 FLT1 IL1RN
2 cardiovascular system MP:0005385 9.87 SOD1 TIMP1 FGF10 FLT1 IL1RN RBP4
3 hematopoietic system MP:0005397 9.86 ELANE FGF10 FLT1 IL1RN ITGAM SELL
4 immune system MP:0005387 9.61 ELANE FGF10 FLT1 IL1RN ITGAM SCGB1A1
5 neoplasm MP:0002006 9.02 ELANE SCGB1A1 SELL SOD1 TIMP1

Drugs & Therapeutics for Bronchopulmonary Dysplasia

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
RespiGam 17 MedImmune Approved January 1996

Drugs for Bronchopulmonary Dysplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 214)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Procaterol Approved Phase 4 72332-33-3 688561
2 Beractant Approved Phase 4,Phase 2,Phase 3 108778-82-1
3
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1 51333-22-3 63006 5281004
4 Poractant alfa Approved Phase 4,Phase 2,Phase 3 129069-19-8
5
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2 57-83-0 5994
6
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
7
Remifentanil Approved Phase 4,Phase 1,Phase 2 132875-61-7 60815
8
Caffeine Approved, Nutraceutical Phase 4,Phase 3 58-08-2 2519
9 Adrenergic Agents Phase 4
10 Adrenergic Agonists Phase 4
11 Adrenergic beta-2 Receptor Agonists Phase 4
12 Adrenergic beta-Agonists Phase 4
13 Albuterol Phase 4
14 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Tocolytic Agents Phase 4,Phase 3,Phase 2
21 Pulmonary Surfactants Phase 4,Phase 3,Phase 2,Phase 1
22 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
23 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
24 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
25 Hormones Phase 4,Phase 3,Phase 2,Phase 1
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
27 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Lactoferrin Phase 4
29 Antibodies Phase 4,Phase 3
30 Immunoglobulins Phase 4,Phase 3
31 Vaccines Phase 4
32 11-hydroxyprogesterone Phase 4,Phase 2,Phase 3
33 17-alpha-hydroxy-progesterone caproate Phase 4,Phase 2,Phase 3
34 Estrogen Antagonists Phase 4,Phase 2,Phase 3
35 Estrogens Phase 4,Phase 2,Phase 3
36 Progestins Phase 4,Phase 3,Phase 2
37 Anticoagulants Phase 4,Phase 3
38 Caffeine citrate Phase 4,Phase 3
39 Central Nervous System Stimulants Phase 4,Phase 3
40 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2
41 Purinergic P1 Receptor Antagonists Phase 4,Phase 3
42 Calcium, Dietary Phase 4
43 Chelating Agents Phase 4
44 Caproate Nutraceutical Phase 4,Phase 2,Phase 3
45 Citrate Nutraceutical Phase 4,Phase 3,Phase 2
46
Citric Acid Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 77-92-9 311
47 Omega 3 Fatty Acid Nutraceutical Phase 4,Phase 3
48 Soy Bean Nutraceutical Phase 4
49 Olive Nutraceutical Phase 4
50
Clarithromycin Approved Phase 3 81103-11-9 84029

Interventional clinical trials:

(show top 50) (show all 272)
id Name Status NCT ID Phase
1 Preterm Infant Inhaled Albuterol Dosing Unknown status NCT02447250 Phase 4
2 Surfactant Administration During Spontaneous Breathing Unknown status NCT01329432 Phase 4
3 Prevention of Chronic Lung Disease (CLD) in Preterm Infants Unknown status NCT00883532 Phase 4
4 Early CPAP in Respiratory Distress Syndrome Unknown status NCT00368680 Phase 4
5 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia Completed NCT00926276 Phase 4
6 Early Versus Late Lactoferrin in Prevention of Neonatal Sepsis Completed NCT02959229 Phase 4
7 Prevention of RSV Infections in Bone Marrow Transplant Recipients Completed NCT00001903 Phase 4
8 Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery Completed NCT00331695 Phase 4
9 Evaluation of Use of Plastic Bags to Prevent Neonatal Hypothermia-Part IV Completed NCT01604447 Phase 4
10 Evaluate the Use of Plastic Bags in Preventing and Treating Hypothermia in Neonates Completed NCT01403623 Phase 4
11 OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP Recruiting NCT02140580 Phase 4
12 Early Caffeine in Preterm Neonates Recruiting NCT03086473 Phase 4
13 Surfactant Via Endotracheal Tube vs. Laryngeal Mask Airway (LMA) in Preterm Neonates With Respiratory Distress Syndrome Recruiting NCT02164734 Phase 4
14 Evaluation of Use of Plastic Bags to Prevent Neonatal Hypothermia-Part III Recruiting NCT01604434 Phase 4
15 Exogenous Surfactant in Very Preterm Neonates in Prevention of Bronchopulmonary Dysplasia Active, not recruiting NCT01039285 Phase 4
16 Rate of Bronchopulmonary Dysplasia in Preterms Neonates: a Trial Comparing SMOFlipid and Medialipide Not yet recruiting NCT02853253 Phase 4
17 Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants Terminated NCT00767039 Phase 4
18 Clarithromycin Prophylaxis in Preterm Infants Colonisation With Ureaplasma Urealyticum and Mycoplasma Hominis Unknown status NCT01652118 Phase 3
19 Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia Unknown status NCT01022580 Phase 3
20 Oral Vitamin A Supplementation in Neonates With Birth Weight < 1500 g Unknown status NCT02102711 Phase 3
21 Cysteine Supplementation in Critically Ill Neonates Unknown status NCT00254176 Phase 2, Phase 3
22 Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia Completed NCT01035190 Phase 3
23 PREMILOC Trial to Prevent Bronchopulmonary Dysplasia in Very Preterm Neonates Completed NCT00623740 Phase 3
24 Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Completed NCT00931632 Phase 3
25 Inhaled Nitric Oxide to Prevent and Treat Bronchopulmonary Dysplasia Completed NCT01503801 Phase 2, Phase 3
26 Phase III Randomized, Double-Blind Study of Dexamethasone Vs Dexamethasone/Methylprednisolone Vs Placebo for Bronchopulmonary Dysplasia Completed NCT00004785 Phase 3
27 Nasal Intermittent Positive Pressure Ventilation in Premature Infants (NIPPV) Completed NCT00433212 Phase 3
28 Inhaled Beclomethasone to Prevent Chronic Lung Disease Completed NCT00000576 Phase 3
29 Post-Hospitalization Nursing Effectiveness (PHONE) Study Completed NCT00314431 Phase 3
30 Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome Completed NCT01203358 Phase 2, Phase 3
31 Inhaled NO in Prevention of Chronic Lung Disease Completed NCT00000548 Phase 3
32 Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide Completed NCT00569530 Phase 3
33 Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants Completed NCT00006401 Phase 3
34 Randomized Trial of Nasal Continuous Positive Airway Pressure or Synchronized Nasal Ventilation in Premature Infants. Completed NCT00188968 Phase 3
35 Vitamin D Supplementation for Extremely Preterm Infants Completed NCT01600430 Phase 2, Phase 3
36 High Frequency Ventilation in Premature Infants (HIFI) Completed NCT00000567 Phase 3
37 Premature Infants in Need of Transfusion (PINT) Completed NCT00182390 Phase 3
38 Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children Completed NCT01006629 Phase 2, Phase 3
39 The Effect of Sildenafil in Preterm Infants With Evolving Chronic Lung Disease Completed NCT00431418 Phase 3
40 Dexamethasone Therapy in VLBW Infants at Risk of CLD Completed NCT00011362 Phase 3
41 Safety and Efficacy Study of Nitric Oxide for Inhalation on Chronic Lung Disease in Premature Babies Completed NCT00551642 Phase 3
42 A Multicenter, Randomized, Open Label Trial of a New Animal Extracted Surfactant to Treat RDS in Preterm Infants Completed NCT02305160 Phase 2, Phase 3
43 Prolonged Outcomes After Nitric Oxide (PrONOx) Completed NCT00234247 Phase 3
44 Safety Study of Home Oxygen Therapy for Children With Acute Bronchiolitis Completed NCT00677066 Phase 3
45 Intravenous Immunoglobulin in Prevention of Preterm Neonatal Sepsis Completed NCT02954926 Phase 3
46 PREGNANT Short Cervix Trial Completed NCT00615550 Phase 3
47 Oxygen Toxicity in the Resuscitation in Extremely Premature Infants Completed NCT00494702 Phase 3
48 Caffeine for Apnea of Prematurity (CAP) Completed NCT00182312 Phase 3
49 Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP) Completed NCT00009646 Phase 3
50 NIV Strategies for RDS in Preterm Infants. NIV (Non Invasive Ventilation), RDS (Respiratory Distress Syndrome) Completed NCT02259400 Phase 2, Phase 3

Search NIH Clinical Center for Bronchopulmonary Dysplasia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bronchopulmonary Dysplasia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bronchopulmonary Dysplasia:
PNEUMOSTEM

Genetic Tests for Bronchopulmonary Dysplasia

Anatomical Context for Bronchopulmonary Dysplasia

MalaCards organs/tissues related to Bronchopulmonary Dysplasia:

39
Lung, Endothelial, Brain, Neutrophil, Testes, Monocytes, Bone
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Bronchopulmonary Dysplasia:
id Tissue Anatomical CompartmentCell Relevance
1 Lung Alveoli Alveolar Epithelial Type 1 Cells Potential therapeutic candidate, affected by disease
2 Lung Alveoli Alveolar Epithelial Type 2 Cells Potential therapeutic candidate, affected by disease
3 Lung Pulmonary Capillary Plexus Affected by disease

Publications for Bronchopulmonary Dysplasia

Articles related to Bronchopulmonary Dysplasia:

(show top 50) (show all 708)
id Title Authors Year
1
GSTP1 and CYP2B6 Genetic Polymorphisms and the Risk of Bronchopulmonary Dysplasia in Preterm Neonates. ( 28081574 )
2017
2
Bronchopulmonary Dysplasia: Chronic Lung Disease of Infancy and Long-Term Pulmonary Outcomes. ( 28067830 )
2017
3
Bronchopulmonary dysplasia and pulmonary hypertension: a meta-analysis. ( 28079864 )
2017
4
Biomarkers associated with bronchopulmonary dysplasia/mortality in premature infants. ( 27893721 )
2017
5
Association between Hemoglobin Levels in the First 3 Days of Life and Bronchopulmonary Dysplasia in Preterm Infants. ( 27120476 )
2016
6
How useful and feasible are early biochemical markers of bronchopulmonary dysplasia? ( 27062476 )
2016
7
Mechanisms of Lung Injury and Bronchopulmonary Dysplasia. ( 27603539 )
2016
8
A new look at bronchopulmonary dysplasia: postcapillary pathophysiology and cardiac dysfunction. ( 28090292 )
2016
9
Differential expression of long non-coding RNAs in hyperoxia-induced bronchopulmonary dysplasia. ( 27137150 )
2016
10
Interdisciplinary Care of Children with Severe Bronchopulmonary Dysplasia. ( 27908648 )
2016
11
Systemic Corticosteroids for the Prevention of Bronchopulmonary Dysplasia: Picking the Right Drug for the Right Baby. ( 27461202 )
2016
12
An arginase-1 SNP that protects against the development of pulmonary hypertension in bronchopulmonary dysplasia enhances NO-mediated apoptosis in lymphocytes. ( 27895230 )
2016
13
Mesenchymal stromal cells in the development and therapy of bronchopulmonary dysplasia. ( 27142639 )
2016
14
A single nucleotide polymorphism in the dimethylarginine dimethylaminohydrolase gene is associated with lower risk of pulmonary hypertension in bronchopulmonary dysplasia. ( 26663142 )
2016
15
Chorioamnionitis at birth does not increase the risk of neurodevelopmental disability in premature infants with bronchopulmonary dysplasia. ( 27552089 )
2016
16
Pathophysiology, screening and diagnosis of pulmonary hypertension in infants with bronchopulmonary dysplasia - A review of the literature. ( 27986502 )
2016
17
Preeclampsia and the Risk of Bronchopulmonary Dysplasia in Preterm Infants Less Than 32 Weeks' Gestation. ( 27919118 )
2016
18
Impact of bronchopulmonary dysplasia on brain and retina. ( 26988760 )
2016
19
Association of Noninvasive Ventilation Strategies With Mortality and Bronchopulmonary Dysplasia Among Preterm Infants: A Systematic Review and Meta-analysis. ( 27532916 )
2016
20
Early Cumulative Supplemental Oxygen Predicts Bronchopulmonary Dysplasia in High Risk Extremely Low Gestational Age Newborns. ( 27470692 )
2016
21
Human mesenchymal stem cells attenuate experimental bronchopulmonary dysplasia induced by perinatal inflammation and hyperoxia. ( 27158330 )
2016
22
MicroRNA in late lung development and bronchopulmonary dysplasia: the need to demonstrate causality. ( 27216745 )
2016
23
Association of TLR polymorphisms with bronchopulmonary dysplasia. ( 27457283 )
2016
24
Ascorbylperoxide Contaminating Parenteral Nutrition Is Associated With Bronchopulmonary Dysplasia or Death in Extremely Preterm Infants. ( 27036126 )
2016
25
Airway Remodeling and Hyperreactivity in a Model of Bronchopulmonary Dysplasia and Their Modulation by IL-1Ra. ( 27482635 )
2016
26
Vitamin D and bronchopulmonary dysplasia in preterm infants. ( 27467562 )
2016
27
Post-Translational Modification of I^-Catenin is Associated with Pathogenic Fibroblastic Changes in Bronchopulmonary Dysplasia. ( 27941077 )
2016
28
Pulmonary Vein Stenosis in Neonates with Severe Bronchopulmonary Dysplasia. ( 26862723 )
2016
29
Postnatal growth restriction augments oxygen-induced pulmonary hypertension in a neonatal rat model of bronchopulmonary dysplasia. ( 27509009 )
2016
30
Cardiac Mechanics in Children with Bronchopulmonary Dysplasia. ( 26506411 )
2016
31
Commentary: A Breath of Fresh Air on the Mesenchyme: Impact of Impaired Mesenchymal Development on the Pathogenesis of Bronchopulmonary Dysplasia. ( 27066487 )
2016
32
An Elevation of Serum Ferritin Level Might Increase Clinical Risk for the Persistence of Patent Ductus Arteriosus, Sepsis and Bronchopulmonary Dysplasia in Erythropoietin-Treated Very-Low-Birth-Weight Infants. ( 27547966 )
2016
33
Where Are We Now with the Role of Steroids in the Management of Bronchopulmonary Dysplasia in Extremely Premature Babies? ( 27559539 )
2016
34
Early Detection for Right Ventricular Dysfunction in Bronchopulmonary Dysplasia without Pulmonary Hypertension. ( 28090250 )
2016
35
Early inhaled nitric oxide in preterm infants <34 weeks with evolving bronchopulmonary dysplasia. ( 27442155 )
2016
36
Inhaled Corticosteroids for Bronchopulmonary Dysplasia: A Meta-analysis. ( 27940717 )
2016
37
Impact of pulmonary hypertension on neurodevelopmental outcome in preterm infants with bronchopulmonary dysplasia: a cohort study. ( 27442157 )
2016
38
Neurally Adjusted Ventilatory Assist in Preterm Infants With Established or Evolving Bronchopulmonary Dysplasia on High-Intensity Mechanical Ventilatory Support: A Single-Center Experience. ( 27918385 )
2016
39
Prophylactic low-dose hydrocortisone treatment increases the rate of survival without bronchopulmonary dysplasia in extremely preterm infants. ( 27516373 )
2016
40
Chorioamnionitis and subsequent bronchopulmonary dysplasia in very-low-birth weight infants: a 25-year cohort. ( 27583395 )
2016
41
Vitamin A Supplementation for Prevention of Bronchopulmonary Dysplasia: Cornerstone of Care or Futile Therapy? ( 27147702 )
2016
42
Association between Breast Milk and Bronchopulmonary Dysplasia: A Single Center Observational Study. ( 27487230 )
2016
43
Antibiotic Exposure and Risk for Death or Bronchopulmonary Dysplasia in Very Low Birth Weight Infants. ( 27908652 )
2016
44
Looking ahead: where to next for animal models of bronchopulmonary dysplasia? ( 27917436 )
2016
45
Oxygen weaning after hospital discharge in children with bronchopulmonary dysplasia. ( 27093064 )
2016
46
Phenotypic assessment of pulmonary hypertension using high-resolution echocardiography is feasible in neonatal mice with experimental bronchopulmonary dysplasia and pulmonary hypertension: a step toward preventing chronic obstructive pulmonary disease. ( 27478373 )
2016
47
Blood Cytokine Profiles Associated with Distinct Patterns of Bronchopulmonary Dysplasia among Extremely Low Birth Weight Infants. ( 27117196 )
2016
48
Expression of transforming growth factor-I^1 in neonatal rats with hyperoxia-induced bronchopulmonary dysplasia and its relationship with lung development. ( 27173325 )
2016
49
Refining anti-inflammatory therapy strategies for bronchopulmonary dysplasia. ( 27957795 )
2016
50
Scoping review shows wide variation in the definitions of bronchopulmonary dysplasia in preterm infants and calls for a consensus. ( 27862302 )
2016

Variations for Bronchopulmonary Dysplasia

Expression for Bronchopulmonary Dysplasia

Search GEO for disease gene expression data for Bronchopulmonary Dysplasia.

Pathways for Bronchopulmonary Dysplasia

Pathways related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.39 CXCL8 ITGAM TIMP1
2 11.18 CXCL8 ELANE FLT1 ITGAM
3 10.82 CXCL8 IL1RN TIMP1

GO Terms for Bronchopulmonary Dysplasia

Cellular components related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.86 ELANE IL1RN ITGAM RBP4 RNASE3 SCGB1A1
2 extracellular region GO:0005576 9.7 CXCL8 ELANE FGF10 FLT1 IL1RN RBP4
3 extracellular space GO:0005615 9.4 CXCL8 ELANE FGF10 FLT1 IL1RN ITGAM
4 secretory granule GO:0030141 9.33 ELANE SCGB1A1 SOD1

Biological processes related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.73 ELANE ITGAM RNASE3 SELL
2 response to lipopolysaccharide GO:0032496 9.63 ELANE FGF10 SCGB1A1
3 chemotaxis GO:0006935 9.54 CXCL8 FGF10 FLT1
4 blood vessel morphogenesis GO:0048514 9.4 FGF10 FLT1
5 embryonic digestive tract development GO:0048566 9.32 CXCL8 FGF10
6 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.26 FGF10 FLT1
7 induction of positive chemotaxis GO:0050930 9.16 CXCL8 FGF10
8 response to organic substance GO:0010033 9.13 SCGB1A1 SOD1 TIMP1
9 female genitalia morphogenesis GO:0048807 8.62 FGF10 RBP4

Molecular functions related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.13 ELANE FGF10 SELL
2 protease binding GO:0002020 8.8 ELANE SELL TIMP1

Sources for Bronchopulmonary Dysplasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....